Congress trades
Bio-Rad Laboratories, Inc. (BIO)
Free on iOS and Android.
About Bio-Rad Laboratories, Inc.
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Norman D. Schwartz
- Employees
- 7,450
- Listed since
- Feb 27, 1980
- Market value
- $9.9B
- Price to earnings (12 mo)
- 44.4
- Net income per share, as reported (12 mo)
- $8.32
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 4, 2026 | $2.62 | $1.75 | $651.0M | $624.0M | EPS beatRevenue beat |
| Q1 FY2026reported Apr 30, 2026 | $1.89 | $1.97 | $592.1M | $589.9M | EPS missRevenue in line |
| Q4 FY2025reported Feb 12, 2026 | $2.51 | $2.57 | $693.2M | $688.8M | EPS missRevenue in line |
| Q3 FY2025reported Oct 29, 2025 | $2.26 | $2.30 | $653.0M | $694.6M | EPS missRevenue miss |
| Q2 FY2025reported Jul 31, 2025 | $2.61 | $1.93 | $651.6M | $633.8M | EPS beatRevenue beat |
| Q1 FY2025reported May 1, 2025 | $2.54 | $1.73 | $585.4M | $573.2M | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | $765.2M | 2,606,219 | +0.1% | 9.74% |
| BlackRock, Inc. | $498.8M | 1,698,929 | +1.1% | 6.35% |
| Dimensional Fund Advisors LP | $277.3M | 944,548 | -13.3% | 3.53% |
| Vanguard Capital Management LLC | $242.8M | 826,972 | -0.5% | 3.09% |
| Ariel Investments, LLC | $239.8M | 816,751 | +3.9% | 3.05% |
| Vanguard Portfolio Management LLC | $239.6M | 816,198 | -1.6% | 3.05% |
| Earnest Partners LLC | $170.5M | 580,752 | -1.4% | 2.17% |
| State Street Corp | $167.9M | 571,762 | +2.2% | 2.12% |
| Bank of America Corp | $144.0M | 490,412 | +10.2% | 1.83% |
| Capital World Investors | $135.8M | 462,457 | +2.8% | 1.73% |
| Capital Research Global Investors | $130.2M | 443,483 | +15.0% | 1.66% |
| UBS Am, A Distinct Business Unit of Ubs Asset Management Americas LLC | $123.0M | 418,884 | -1.7% | 1.57% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in BIO
20 disclosures of 22 on record · median 31d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +28.5%After the saleS&P 500 +74.9% · -46.4 pts vs S&P 500 | Nov 3, 2023 | Dec 6, 2023 | 33d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +5.2%S&P 500 +77.9% · -72.7 pts vs S&P 500 | Oct 2, 2023 | Nov 8, 2023 | 37d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +26.9%After the saleS&P 500 +84.3% · -57.4 pts vs S&P 500 | Oct 26, 2023 | Nov 8, 2023 | 13d |
| Lois Frankel | Stock | Sale | $1,001 - $15,000 | +3.4%After the saleS&P 500 +70.6% · -67.3 pts vs S&P 500 | Sep 8, 2023 | Oct 10, 2023 | 32d |
| Lois Frankel | Stock | Purchase | $1,001 - $15,000 | +1.5%S&P 500 +73.5% · -72.0 pts vs S&P 500 | Jun 28, 2023 | Jul 28, 2023 | 30d |
| Lois Frankel | Stock | Purchase | $1,001 - $15,000 | -1.4%S&P 500 +73.6% · -75.0 pts vs S&P 500 | Jun 29, 2023 | Jul 28, 2023 | 29d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -1.4%After the saleS&P 500 +73.6% · -75.0 pts vs S&P 500 | Jun 29, 2023 | Jul 11, 2023 | 12d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | -10.8%After the saleS&P 500 +86.5% · -97.3 pts vs S&P 500 | Nov 30, 2022 | Dec 29, 2022 | 29d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +1.3%S&P 500 +105.0% · -103.6 pts vs S&P 500 | Nov 3, 2022 | Dec 6, 2022 | 33d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -20.2%After the saleS&P 500 +106.7% · -126.9 pts vs S&P 500 | Jun 17, 2022 | Jul 7, 2022 | 20d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -24.5%S&P 500 +90.4% · -115.0 pts vs S&P 500 | May 10, 2022 | Jun 10, 2022 | 31d |
| Tommy TubervilleJoint | Stock | Sale (Full) | $1,001 - $15,000 | -36.2%After the saleS&P 500 +65.7% · -101.9 pts vs S&P 500 | Mar 30, 2022 | Apr 8, 2022 | 9d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -49.4%After the saleS&P 500 +73.2% · -122.7 pts vs S&P 500 | Oct 7, 2021 | Nov 9, 2021 | 33d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | -35.1%S&P 500 +92.0% · -127.1 pts vs S&P 500 | Mar 29, 2021 | Jul 23, 2021 | 116d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | -36.7%After the saleS&P 500 +104.7% · -141.4 pts vs S&P 500 | Jan 5, 2021 | Feb 10, 2021 | 36d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | -27.6%After the saleS&P 500 +127.8% · -155.3 pts vs S&P 500 | Oct 2, 2020 | Dec 8, 2020 | 67d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | -0.1%After the saleS&P 500 +186.7% · -186.8 pts vs S&P 500 | Apr 7, 2020 | Jun 15, 2020 | 69d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | -21.4%After the saleS&P 500 +150.3% · -171.7 pts vs S&P 500 | May 27, 2020 | Jun 15, 2020 | 19d |
| Susie LeeJoint | Stock | Sale | $1,001 - $15,000 | +0.4%After the saleS&P 500 +135.5% · -135.0 pts vs S&P 500 | Dec 27, 2019 | Jan 16, 2020 | 20d |
| Susie LeeJoint | Stock | Purchase | $1,001 - $15,000 | +22.7%S&P 500 +160.3% · -137.6 pts vs S&P 500 | Jun 25, 2019 | Jul 18, 2019 | 23d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in BIO, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded BIO?
Ro Khanna, Lois Frankel, Susie Lee and Tommy Tuberville disclosed BIO transactions in the filings shown here.
How quickly are BIO trades disclosed?
Congressional disclosures took a median of 31 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.